BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7924220)

  • 1. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
    Aldridge KE; Ashcraft D; O'Brien M; Sanders CV
    Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
    Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
    Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMY28142, cefbuperazone (T-1982), and Sch 34343. Antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1985 May; 3(3):263-8. PubMed ID: 3838925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
    Snydman DR; Jacobus NV; McDermott LA; Supran S; Cuchural GJ; Finegold S; Harrell L; Hecht DW; Iannini P; Jenkins S; Pierson C; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
    Downes J; Andrew JH
    Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
    Snydman DR; McDermott L; Cuchural GJ; Hecht DW; Iannini PB; Harrell LJ; Jenkins SG; O'Keefe JP; Pierson CL; Rihs JD; Yu VL; Finegold SM; Gorbach SL
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S54-65. PubMed ID: 8953108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.